So, you know how it goes in biotech: a small company gets some promising data, its stock starts climbing, and suddenly everyone's whispering about which Big Pharma giant is going to swoop in and buy it. That's been the story for French biotech Abivax SA (ABVX) for months. But according to CEO Marc de Garidel, the company isn't exactly sitting by the phone waiting for a suitor to call. Instead, he's talking about raising more money.

In a recent interview, de Garidel downplayed the urgency to sell, telling CNBC the company is focused on independent growth. This comes despite analysts consistently flagging Abivax as a prime acquisition target. The rumor mill has been busy, with names like AstraZeneca Plc (AZN) and Eli Lilly and Co (LLY) floated as potential buyers. AstraZeneca even had to publicly deny the chatter. But management's latest comments suggest they're more interested in building the company than cashing out.

The plan, it seems, is to get through a major clinical milestone first, then go to the market for cash.

The Big Test in June

All eyes are on June. That's when Abivax expects to report top-line results from its second late-stage trial for obefazimod, its lead drug candidate for ulcerative colitis. This isn't just another data point; it's the final piece of the puzzle for the drug's long-term maintenance effect. The trial, called ABTECT-UC, has been chugging along with nearly 90% of participants completing the 44-week treatment, and a safety board recently gave it a clean bill of health.

If the data is positive—and the company's stock skyrocketed last July on overwhelmingly positive results from earlier trials—Abivax plans to submit for U.S. Food and Drug Administration approval in the fourth quarter. This is the classic biotech inflection point: prove your drug works, and the world (or at least investors and potential partners) starts to take you very seriously.

Follow the Money (They Plan to Raise)

Here's where the CEO's comments get practical. De Garidel indicated that after the trial readout, Abivax is likely to pursue a capital raise. We're talking a mix of equity and debt financing, with funding needs expected to reach "several million dollars." The company is still figuring out the exact size and timing, but the goal is to secure enough capital to advance operations toward profitability.

Now, you might be thinking: wait, didn't they just raise a ton of money? Yes. In July 2025, right after that last batch of great data, the company raised around $650 million. And as of the end of last year, they were sitting on a very comfortable pile of cash, cash equivalents, and short-term investments totaling about $614.4 million. That's enough to keep the lights on into the fourth quarter of 2027.

So why raise more? It's all about the runway to commercialization. Bringing a drug to market is expensive. Filing with regulators, scaling up manufacturing, and—most importantly—launching the product costs a fortune. The post-June raise would be about bridging the gap from a successful trial to a commercially viable company. It's a signal that they're planning for a future as a standalone entity, not just a science project waiting for a buyer.

Going Global, But Not Alone

Speaking of going it alone, Abivax is also being realistic about its size. With only about 150 employees, the company knows it can't launch its drug worldwide by itself. The plan, according to the CNBC report, is to seek commercial partners for markets outside the U.S. after the maintenance data is out. They're keeping their options open, noting that multiple partnerships could be on the table depending on who's interested and what makes strategic sense.

This is a smart, flexible approach. It lets them retain control and value in the lucrative U.S. market while leveraging partners' existing sales forces and expertise elsewhere. It's the biotech playbook: do the hard science, prove it works, then let the big commercial machines help you sell it.

As for the stock, Abivax shares were down about 4.8% on the day of the report. In the volatile world of clinical-stage biotech, a little pullback on a day when the CEO says "we're not selling" isn't exactly shocking. The real movement will come in June, when the data tells the next chapter of the story.